Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
ConditionBreast Cancer Screening
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-75
SponsorGeneplus-Beijing Co. Ltd.
About this trial
The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. It will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.
Eligibility criteria
Qualifiers
With confirmed pathological diagnosis and molecular subtyping results
Ability to provide a written informed consent
Disqualifiers
Patients with a history of or currently suffering from other malignancies
Pregnant or planning to become pregnant female patients
Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw
Patients with a history of blood transfusion within the past month
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 2 trial groupsLocations
1Cancer Institute and Hospital, Chinese Academy of Medical Sciences100021, BeijingBeijing Municipality, China
Sponsors and collaborators
Geneplus-Beijing Co. Ltd.
Lead sponsor
Chinese Academy of Medical Sciences
Collaborator
Source ClinicalTrials.gov